Veracyte Inc (VCYT)
19.45
+0.25
(+1.30%)
USD |
NASDAQ |
Apr 19, 16:00
19.45
0.00 (0.00%)
After-Hours: 20:00
Veracyte Enterprise Value: 1.225B for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 1.225B |
| April 17, 2024 | 1.199B |
| April 16, 2024 | 1.204B |
| April 15, 2024 | 1.238B |
| April 12, 2024 | 1.302B |
| April 11, 2024 | 1.340B |
| April 10, 2024 | 1.338B |
| April 09, 2024 | 1.392B |
| April 08, 2024 | 1.337B |
| April 05, 2024 | 1.294B |
| April 04, 2024 | 1.298B |
| April 03, 2024 | 1.332B |
| April 02, 2024 | 1.323B |
| April 01, 2024 | 1.408B |
| March 28, 2024 | 1.447B |
| March 27, 2024 | 1.414B |
| March 26, 2024 | 1.372B |
| March 25, 2024 | 1.360B |
| March 22, 2024 | 1.367B |
| March 21, 2024 | 1.403B |
| March 20, 2024 | 1.406B |
| March 19, 2024 | 1.410B |
| March 18, 2024 | 1.404B |
| March 15, 2024 | 1.367B |
| March 14, 2024 | 1.379B |
| Date | Value |
|---|---|
| March 13, 2024 | 1.440B |
| March 12, 2024 | 1.459B |
| March 11, 2024 | 1.485B |
| March 08, 2024 | 1.489B |
| March 07, 2024 | 1.491B |
| March 06, 2024 | 1.461B |
| March 05, 2024 | 1.506B |
| March 04, 2024 | 1.550B |
| March 01, 2024 | 1.585B |
| February 29, 2024 | 1.551B |
| February 28, 2024 | 1.568B |
| February 27, 2024 | 1.557B |
| February 26, 2024 | 1.552B |
| February 23, 2024 | 1.449B |
| February 22, 2024 | 1.567B |
| February 21, 2024 | 1.581B |
| February 20, 2024 | 1.617B |
| February 16, 2024 | 1.596B |
| February 15, 2024 | 1.637B |
| February 14, 2024 | 1.654B |
| February 13, 2024 | 1.545B |
| February 12, 2024 | 1.727B |
| February 09, 2024 | 1.657B |
| February 08, 2024 | 1.615B |
| February 07, 2024 | 1.568B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
643.66M
Minimum
Mar 18 2020
5.083B
Maximum
Feb 09 2021
1.751B
Average
1.606B
Median
Enterprise Value Benchmarks
| Fonar Corp | 47.49M |
| XWELL Inc | -9.224M |
| ProPhase Labs Inc | 103.69M |
| Applied DNA Sciences Inc | 2.269M |
| OncoCyte Corp | 25.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.29M |
| Revenue (Quarterly) | 98.20M |
| Total Expenses (Quarterly) | 101.17M |
| EPS Diluted (Quarterly) | -0.39 |
| Gross Profit Margin (Quarterly) | 70.09% |
| Profit Margin (Quarterly) | -28.81% |
| Earnings Yield | -5.30% |
| Normalized Earnings Yield | -0.7973 |